203 related articles for article (PubMed ID: 2841246)
1. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus.
Gregory CD; Edwards CF; Milner A; Wiels J; Lipinski M; Rowe M; Tursz T; Rickinson AB
Int J Cancer; 1988 Aug; 42(2):213-20. PubMed ID: 2841246
[TBL] [Abstract][Full Text] [Related]
2. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype.
Gregory CD; Tursz T; Edwards CF; Tetaud C; Talbot M; Caillou B; Rickinson AB; Lipinski M
J Immunol; 1987 Jul; 139(1):313-8. PubMed ID: 2953817
[TBL] [Abstract][Full Text] [Related]
3. Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.
Ehlin-Henriksson B; Manneborg-Sandlund A; Klein G
Int J Cancer; 1987 Feb; 39(2):211-8. PubMed ID: 3026973
[TBL] [Abstract][Full Text] [Related]
4. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines.
Rooney CM; Gregory CD; Rowe M; Finerty S; Edwards C; Rupani H; Rickinson AB
J Natl Cancer Inst; 1986 Sep; 77(3):681-7. PubMed ID: 2943927
[TBL] [Abstract][Full Text] [Related]
5. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.
Wang F; Gregory CD; Rowe M; Rickinson AB; Wang D; Birkenbach M; Kikutani H; Kishimoto T; Kieff E
Proc Natl Acad Sci U S A; 1987 May; 84(10):3452-6. PubMed ID: 3033649
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.
Gregory CD; Murray RJ; Edwards CF; Rickinson AB
J Exp Med; 1988 Jun; 167(6):1811-24. PubMed ID: 2898508
[TBL] [Abstract][Full Text] [Related]
8. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
Misko IS; Schmidt C; Martin N; Moss DJ; Sculley TB; Burrows S; Burman KJ
Int J Cancer; 1990 Sep; 46(3):399-404. PubMed ID: 2168343
[TBL] [Abstract][Full Text] [Related]
10. Expression of interleukin 10 in B lymphocytes of different origin.
Finke J; Ternes P; Lange W; Mertelsmann R; Dölken G
Leukemia; 1993 Nov; 7(11):1852-7. PubMed ID: 7694007
[TBL] [Abstract][Full Text] [Related]
11. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype.
Falk MH; Trauth BC; Debatin KM; Klas C; Gregory CD; Rickinson AB; Calender A; Lenoir GM; Ellwart JW; Krammer PH
Blood; 1992 Jun; 79(12):3300-6. PubMed ID: 1375849
[TBL] [Abstract][Full Text] [Related]
12. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
13. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.
Cutrona G; Ulivi M; Fais F; Roncella S; Ferrarini M
J Exp Med; 1995 Feb; 181(2):699-711. PubMed ID: 7836923
[TBL] [Abstract][Full Text] [Related]
14. A monoclonal antibody with anti-Burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines.
Wiels J; Lenoir GM; Fellous M; Lipinski M; Salomon JC; Tetaud C; Tursz T
Int J Cancer; 1982 Jun; 29(6):653-8. PubMed ID: 6286514
[TBL] [Abstract][Full Text] [Related]
15. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma.
Rowe M; Rooney CM; Edwards CF; Lenoir GM; Rickinson AB
Int J Cancer; 1986 Mar; 37(3):367-73. PubMed ID: 3005176
[TBL] [Abstract][Full Text] [Related]
17. EBNA promoter usage in EBV-negative Burkitt lymphoma cell lines converted with a neomycin-resistant EBV strain.
Maeda A; Kiss C; Chen F; Ehlin-Henriksson B; Nagy N; Szekely L; Takada K; Klein E; Klein G
Int J Cancer; 2001 Sep; 93(5):714-9. PubMed ID: 11477584
[TBL] [Abstract][Full Text] [Related]
18. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma.
Rowe M; Rooney CM; Rickinson AB; Lenoir GM; Rupani H; Moss DJ; Stein H; Epstein MA
Int J Cancer; 1985 Apr; 35(4):435-41. PubMed ID: 2985508
[TBL] [Abstract][Full Text] [Related]
19. Local growth of a Burkitt's lymphoma versus disseminated invasive growth of the autologous EBV-immortalized lymphoblastoid cells and their somatic cell hybrids in SCID mice.
Walter J; Möller P; Moldenhauer G; Schirrmacher V; Pawlita M; Wolf J
Int J Cancer; 1992 Jan; 50(2):265-73. PubMed ID: 1309726
[TBL] [Abstract][Full Text] [Related]
20. EBV-negative and -positive Burkitt cell lines variably express receptors for B-cell activation and differentiation.
Favrot MC; Maritaz O; Suzuki T; Cooper M; Philip I; Philip T; Lenoir G
Int J Cancer; 1986 Dec; 38(6):901-6. PubMed ID: 3025106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
